We are live on ! Find out more
PPBT

Purple Biotech

5 hedge funds and large institutions have $273K invested in Purple Biotech in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0%0% (-0%)

15% less capital invested

Capital invested by funds: $321K → $273K (-$48K)

29% less funds holding

Funds holding: 75 (-2)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
1
Deutsche Bank
Germany
$101K -$14.9K -4 -14%
ARTA
2
A.R.T. Advisors
New York
$81K +$70.8K +19 New
MC
3
Menta Capital
California
$71K -$70.8K -19 -53%
Wells Fargo
4
Wells Fargo
California
$18K +$14.9K +4 New
AG
5
Advisor Group
Arizona
$2K -$29.8K -8 -89%
PVH
6
Psagot Value Holdings
Israel
-$53K -17 Closed
Citadel Advisors
7
Citadel Advisors
Florida
-$17K -6 Closed
UBS Group
8
UBS Group
Switzerland
-$6K -2 Closed

PPBT Hedge Fund Activity: Q3 2017 in Review

5 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q3 2017, worth a combined $273K — down 15% from $321K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of PPBT and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.

The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $70.8K. The largest seller was Menta Capital, cutting an estimated $70.8K.

  • 5 institutional investors held Purple Biotech (PPBT) as of Q3 2017, down from 7 in Q2 2017.
  • Funds reported $273K of Purple Biotech stock for Q3 2017, down 15% quarter-over-quarter.
  • 2 funds opened new Purple Biotech positions in Q3 2017 and 3 closed out, a net change of -1 holder.
  • The largest Purple Biotech buyer in Q3 2017 was A.R.T. Advisors, an estimated $70.8K added.
  • The largest Purple Biotech seller in Q3 2017 was Menta Capital, an estimated $70.8K sold.

Based on aggregated 13F filings for Q3 2017.